CLINICAL TRIALS PROFILE FOR SECRETIN SYNTHETIC HUMAN
✉ Email this page to a colleague
All Clinical Trials for SECRETIN SYNTHETIC HUMAN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00036231 ↗ | Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction | Terminated | Repligen Corporation | Phase 3 | 2002-04-01 | The purpose of the study is to determine the effect of multiple doses of secretin on autism. |
| NCT00036244 ↗ | Synthetic Human Secretin in Children With Autism | Completed | Repligen Corporation | Phase 3 | 2002-04-01 | The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism. |
| NCT00065962 ↗ | Secretin for the Treatment of Autism | Completed | National Institute on Deafness and Other Communication Disorders (NIDCD) | Phase 3 | 1999-06-01 | Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms. |
| NCT00065962 ↗ | Secretin for the Treatment of Autism | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 3 | 1999-06-01 | Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms. |
| NCT00216294 ↗ | Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder | Completed | Repligen Corporation | Phase 2 | 2005-02-01 | The purpose of this study is to determine the safety and tolerability of RG1068 (Synthetic Human Secretin) when administered three times weekly to outpatients with obsessive compulsive disorder (OCD), to determine the impact of multiple subcutaneous injections of RG1068 on the symptoms of OCD, as measured by changes in clinical scales, and to evaluate the effect of RG1068 on ODC patients' anxiety, quality of life, and depression. |
| NCT00216294 ↗ | Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder | Completed | Shekhar, Anantha M.D., Ph.D. | Phase 2 | 2005-02-01 | The purpose of this study is to determine the safety and tolerability of RG1068 (Synthetic Human Secretin) when administered three times weekly to outpatients with obsessive compulsive disorder (OCD), to determine the impact of multiple subcutaneous injections of RG1068 on the symptoms of OCD, as measured by changes in clinical scales, and to evaluate the effect of RG1068 on ODC patients' anxiety, quality of life, and depression. |
| NCT00216294 ↗ | Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder | Completed | Indiana University School of Medicine | Phase 2 | 2005-02-01 | The purpose of this study is to determine the safety and tolerability of RG1068 (Synthetic Human Secretin) when administered three times weekly to outpatients with obsessive compulsive disorder (OCD), to determine the impact of multiple subcutaneous injections of RG1068 on the symptoms of OCD, as measured by changes in clinical scales, and to evaluate the effect of RG1068 on ODC patients' anxiety, quality of life, and depression. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SECRETIN SYNTHETIC HUMAN
Condition Name
Clinical Trial Locations for SECRETIN SYNTHETIC HUMAN
Trials by Country
Clinical Trial Progress for SECRETIN SYNTHETIC HUMAN
Clinical Trial Phase
Clinical Trial Sponsors for SECRETIN SYNTHETIC HUMAN
Sponsor Name
